Damoctocog alfa pegol was considered by the clinicians involved in the survey as the FVIII of first choice, compared with other EHLs, in many types of patients: sporty and active; those with chronic pain, arthropathy or synovitis; those with a severe bleeding phenotype; and those with poor autonomy or difficult venous access. This evidence concerns the gene F8 and arthropathy.